10:40 : United Therapeutics ([[UTHR]] -2.6%) shares are downgraded to Market Perfo -
United Therapeutics (UTHR -2.6%) shares are downgraded to Market Perform from Outperform with a new price target of $48 from $65 by Leerink Swann, which cites generic risk to its treatment of pulmonary arterial hypertension. ...
07:28 : United Therapeutics (UTHR) files a patent infringement lawsuit against ... -
United Therapeutics (UTHR) files a patent infringement lawsuit against Novartis' (NVS) Sandoz unit over patents related to a pulmonary hypertension drug. Sandoz aims to sell a generic version of United's Remdoulin drug. NVS ...